Creative Biolabs Supports Early Oncology Drug Discovery Through Mechanistic Research and ADME Assessment
Creative Biolabs combines oncology research capabilities with non-coding RNA characterisation and in vitro drug profiling to help research teams evaluate biological rationale alongside candidate developability.
Creative Biolabs offers complementary services spanning tumour biology and in vitro drug assessment, supporting biotechnology, pharmaceutical and academic teams as they plan early oncology research programmes. The portfolio addresses two questions that influence candidate selection: whether a proposed target has a convincing biological rationale and whether a candidate molecule has properties compatible with its intended use.
For emerging biotechnology companies, these questions also shape how limited research budgets are allocated. A molecular finding may justify further investigation, but its relevance needs to be tested in an appropriate biological model. Equally, activity in a cell assay provides only part of the evidence needed to assess a candidate. Bringing mechanism and developability into early study planning can help teams identify which uncertainties require attention before larger commitments are made.
Creative Biolabs’ basic oncology research services cover areas including genomic instability, epigenetic regulation, cancer signalling and metabolic reprogramming. Customised cellular models and target validation can support investigations into the processes that sustain tumour growth or contribute to resistance. These capabilities provide a foundation for designing experiments around the biological question, rather than relying on a single molecular readout.
For example, a candidate target associated with tumour proliferation may require functional validation in a disease-relevant cellular model before researchers can determine whether the observed association supports further drug discovery work.
Non-coding RNA research adds a further layer of mechanistic investigation. Changes in RNA expression can highlight candidates for study, but functional analysis is needed to establish how those candidates influence cellular behaviour. This distinction matters when prioritising potential targets or interpreting signatures associated with disease progression.
Through its integrated non-coding RNA characterisation services, Creative Biolabs supports miRNA and lncRNA profiling, circulating RNA analysis, and investigation of RNA–protein interactions. Multi-omics analysis brings RNA profiles together with genomic and methylation data, while functional validation helps researchers investigate the significance of selected findings. The service connects initial discovery with follow-up studies of regulatory mechanisms.
As programmes move towards candidate evaluation, study design must also reflect the molecule and intended route of administration. For small-molecule oncology programmes, absorption and metabolic behaviour are important considerations alongside target activity. Different therapeutic modalities require different assessment strategies, so the testing panel should be selected for the specific development question.
Once a target has sufficient mechanistic support and a candidate has demonstrated relevant biological activity, the next question is whether its physicochemical and disposition-related properties justify further development.
Creative Biolabs’ in vitro ADME solutions bring together assays relevant to absorption, distribution, metabolism, and excretion. Available areas include solubility and permeability assessment, plasma stability, blood partitioning, and enzyme- and transporter-related studies. Selecting complementary tests can help teams investigate properties that warrant optimisation and determine which candidates merit further evaluation.
For programmes considering oral delivery, the company’s Caco-2 permeability analysis services provide a focused assessment of intestinal epithelial transport. The platform uses Caco-2 cell monolayers, with transepithelial electrical resistance measurements to assess barrier integrity and HPLC-MS/MS detection to quantify compound transport. The model can inform investigations of passive diffusion, active transport, and efflux-related absorption limitations.
These results should be interpreted within the scope of the assay. Intestinal permeability data address an absorption question; they do not establish penetration into tumour tissue. Similarly, an in vitro profile provides evidence for subsequent development decisions, with further studies needed to evaluate behaviour in more complex biological systems.
By making mechanistic research and candidate profiling available within its oncology service portfolio, Creative Biolabs supports research teams seeking a clearer basis for experimental prioritisation. Researchers developing oncology candidates can explore Creative Biolabs’ mechanistic research and in vitro ADME services to identify experimental approaches suited to their target, molecular modality, and current development questions.
About Creative Biolabs
Creative Biolabs provides custom research services for oncology and drug discovery. Its capabilities include tumour biology investigations, non-coding RNA characterisation, and in vitro ADME assessment for biotechnology, pharmaceutical, and academic research programmes.
